Blood
Articles in this Issue
Lactate export inhibition reveals a metabolic vulnerability in myelofibrosis
Abstract Myelofibrosis (MF) is a debilitating myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, constitutional...
Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma
Abstract Background: Treatment of relapsed/refractory multiple myeloma (RRMM) and frail newly diagnosed multiple myeloma (NDMM) patients rem...
Uncovering bispecific antibody mechanisms via 3D superresolution imaging of T cell-tumor cell membrane contacts
Abstract Uncovering bispecific antibody mechanisms via 3D superresolution imaging of T cell-tumor cell membrane contacts Introduction: Bispe...
Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1
Abstract Background: Anitocabtagene autoleucel (anito-cel) is an autologous anti–BCMA chimeric antigen receptor (CAR) T-cell therapy with a...
Mechanistic approach exploring combination agents to potentiate anti-leukemia activity of Hu8F4, a clinical stage T cell receptor mimic antibody
Abstract Hu8F4 is a T cell receptor (TCR)-mimic antibody that binds the leukemia-associated PR1/HLA-A2 complex overexpressed on HLA-A2+ leuk...
Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies
Abstract Introduction CD20-targeting monoclonal antibodies (mAbs) are in clinical use and standard of care in the treatment of hematological...
Curable but not equal: Survival disparities in classic Hodgkin lymphoma by treatment facility type in the United States
Abstract Background: Classic Hodgkin lymphoma (cHL) has an estimated global incidence of 85,000 cases annually and prima...
Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study
Abstract Introduction Transplant-eligible NDMM (TE-NDMM) exhibits heterogeneous risk profiles requiring tailored approaches. We evaluated th...
Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma
Abstract Objective：Given the poor prognosis of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), we compared the efficacy and safety...
A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl
Abstract Background and Significance: Pegaspargase-based therapy for acute lymphoblastic leukemia (ALL) offers well-established benefits but...
Evaluating artificial intelligence (AI) as a clinical decision support tool for AML patients
Abstract INTRODUCTION Acute myeloid leukemia (AML) represents a heterogeneous group of hematologic malignancies requiring highly individualiz...
Genomic assessment of acquired mutations in participants with CLL/SLL treated with nemtabrutinib in the Phase 2 bellwave-003 study
Abstract Introduction: Nemtabrutinib is a once daily, noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi) that targets BTK and o...
Short-term erythrocytapheresis is associated with resolution of vertebral osteonecrosis in children with sickle cell disease
Abstract Introduction: Chronic erythrocytapheresis or red cell exchange transfusion therapy (RCE) is used to maintain low hemoglobin S levels...
Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial
Abstract Introduction: Myelofibrosis is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, and debil...
Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis
Abstract Background: The 2022 WHO classification introduced Myelodysplastic Syndrome with fibrosis (MDS-f) as a distinct morphological catego...
Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma
Abstract Serum monoclonal protein (M-protein) levels, typically measured via serum protein electrophoresis (SPEP), remain a cornerstone in t...
Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis
Abstract Introduction Long-term TKI therapy for patients (pts) with CML is efficacious but is associated with adverse events (AEs) affecting...
Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States
Abstract Introduction: Cytopenia in patients with myelofibrosis (MF) is characterized by presence of anemia and/or thrombocytopenia, and is...
Race-related molecular differences in SLAMF7 expression drive disparities in multiple myeloma outcomes
Abstract Background: African Americans (AA) experience earlier onset and a 2-3 fold higher incidence of multiple myeloma (MM) compared to Wh...
Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma
Abstract Introduction: Daratumumab (Dara), an anti-CD38 antibody, is approved for the treatment of patients with multiple myeloma (MM) and r...
Impact of hematopoietic lineage-specific deletion of CYB5R3 on steady-state and stress erythropoiesis In Vivo
Abstract Background: Cytochrome b5 reductase 3 (CYB5R3) is a reductase that modulates oxidative signaling by reducing substrates such as hem...
Inpatient systemic therapy for CLL/SLL in the United States, 2016–2022: Trends, disparities, and the shift from chemotherapy to monoclonal antibodies
Abstract Background: Though CLL/SLL care has shifted to outpatient targeted and immune therapies, contemporary national patterns of inpatien...
A 12-year retrospective analysis of surveillance strategy in young adults after complete remission from aggressive lymphomas
Abstract Background After complete remission from high-risk lymphomas, including classical Hodgkin's lymphoma (cHL), dif...
Peripheral blood dendritic cell subtype alterations in polycythemia vera: Clinical correlations with disease risk and inflammatory profile
Abstract Background: Polycythemia vera (PV) is characterized by chronic inflammation and immune dysfunction, yet the role of dendritic cells...
Tumor-infiltrating lymphocyte therapy in lung cancer: A systematic review
Abstract Background: Lung cancer remains the leading cause of cancer-related deaths, with over 124,000 deaths projected in the U.S. in 2025....